Janosch Ortmann

Janosch Ortmann

Auto-generated profile, based on publicly available information

Janosch Ortmann

Département AOTI, Université du Québec à Montréal

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Acta Mathematica
Verified
Journal Article
Open access
PDF file
DDDuncan Dauvergne
Duncan Dauvergne
JOJanosch Ortmann
Janosch Ortmann
BVBálint Virág
Bálint Virág
International Press of Boston - publishers of scholarly mathematical and scientific journals and books

29 February 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
PHPedro Horna
Pedro Horna
MWMatthew Weybright
Matthew Weybright
MFMathieu Ferrari
Mathieu Ferrari
DJDennis Jungherz
Dennis Jungherz
YPYaYi Peng
YaYi Peng
HOHoratiu Olteanu
Horatiu Olteanu
The diagnosis of leukemic T-cell malignancies is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. Recently developed therapeutic antibodies specific for the mutually exclusive T-cell receptor constant β chain (TRBC)1 and TRBC2 isoforms provide a unique opportunity to assess for TRBC-restriction as a surrogate of clonality in the flow cytometric analysis of T-cell neoplasms. To demonstrate the diagnostic utility of this approach, we studied 164 clinical specimens with (60) or without (104) T-cell neoplasia, in addition to 39 blood samples from healthy donors. Dual TRBC1 and TRBC2 expression was studied within a comprehensive T-cell panel, in a fashion similar to the routine evaluation of kappa and lambda immunoglobulin light chains for the detection of clonal B-cells. Polytypic TRBC expression was demonstrated on total, CD4+ and CD8+ T-cells from all healthy donors; and by intracellular staining on benign T-cell precursors. All neoplastic T-cells were TRBC-restricted, except for 8 cases (13%) lacking TRBC expression. T-cell clones of uncertain significance were identified in 17 samples without T-cell malignancy (13%) and accounted for smaller subsets than neoplastic clones (median: 4.7 vs. 69% of lymphocytes, p < 0.0001). Single staining for TRBC1 produced spurious TRBC1-dim subsets in 24 clinical specimens (15%), all of which resolved with dual TRBC1/2 staining. Assessment of TRBC restriction by flow cytometry provides a rapid diagnostic method to detect clonal T-cells, and to accurately determine the targetable TRBC isoform expressed by T-cell malignancies.

2 January 2021 in Annals of Operations Research
Verified
Journal Article
Closed access
PDF file
MHMike Hewitt
Mike Hewitt
JOJanosch Ortmann
Janosch Ortmann
WRWalter Rei
Walter Rei

1 September 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
AMArvind Singh Mer
Arvind Singh Mer
WBWail Ba-Alawi
Wail Ba-Alawi
PSPetr Smirnov
Petr Smirnov
YWYi Xiao Wang
Yi Xiao Wang
BBBen Brew
Ben Brew
BHBenjamin Haibe-Kains
Benjamin Haibe-Kains
Identifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for in vivo pharmacogenomic datasets that allows for quantification of variability in gene expression and pathway activity across PDX passages. We found that only a few genes and pathways exhibited passage-specific alterations and were therefore not suitable for biomarker discovery. Using the largest PDX pharmacogenomic dataset to date, we identified 87 pathways that are significantly associated with response to 51 drugs (FDR < 0.05). We found novel biomarkers based on gene expressions, copy number aberrations, and mutations predictive of drug response (concordance index > 0.60; FDR < 0.05). Our study demonstrates that Xeva provides a flexible platform for integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive of drug response, representing a major step forward in precision oncology. Significance: A computational platform for PDX data analysis reveals consistent gene and pathway activity across passages and confirms drug response prediction biomarkers in PDX. See related commentary by Meehan, p. 4324

15 March 2023 in Computational Management Science
Verified
Journal Article
Closed access
PDF file
JKJulien Keutchayan
Julien Keutchayan
JOJanosch Ortmann
Janosch Ortmann
WRWalter Rei
Walter Rei

1 May 2021 in International Journal of Nursing Studies
Verified
Journal Article
Closed access
MPMarie-Douce Primeau
Marie-Douce Primeau
ISIsabelle St-Pierre
Isabelle St-Pierre
JOJanosch Ortmann
Janosch Ortmann
KKKelley Kilpatrick
Kelley Kilpatrick
CCChristine L. Covell
Christine L. Covell